Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Completed · Phase 3 · Has a placebo group
Conditions studied: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
In brief
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).
Key facts
- Study ID
- NCT04362813
- Run by
- Novartis Pharmaceuticals
- People needed
- 454
- Starts
- 2020-04-30
- Expected to finish
- 2020-12-22
- Last updated by the study team
- 2022-01-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Boston, Massachusetts, United States
- Novartis Investigative Site — Boston, Massachusetts, United States
- Novartis Investigative Site — Brooklyn, New York, United States
- Novartis Investigative Site — Chapel Hill, North Carolina, United States
- Novartis Investigative Site — Cleveland, Ohio, United States
- Novartis Investigative Site — Philadelphia, Pennsylvania, United States
- Novartis Investigative Site — Houston, Texas, United States
- Novartis Investigative Site — Richmond, Virginia, United States
- Novartis Investigative Site — Tacoma, Washington, United States
- Novartis Investigative Site — Toulouse, France
- Novartis Investigative Site — Bergamo, BG, Italy
- Novartis Investigative Site — Cona, FE, Italy
- Novartis Investigative Site — Barnaul, Russia
- Novartis Investigative Site — Moscow, Russia
- Novartis Investigative Site — Moscow, Russia
- Novartis Investigative Site — Moscow, Russia
- Novartis Investigative Site — Moscow, Russia
- Novartis Investigative Site — Ryazan, Russia
- Novartis Investigative Site — S-Petersburg, Russia
- Novartis Investigative Site — Saint Petersburg, Russia
- Novartis Investigative Site — Saint Petersburg, Russia
- Novartis Investigative Site — Sestroretsk, Russia
- Novartis Investigative Site — L'Hospitalet de Llobregat, Barcelona, Spain
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — San Sebastián de los Reyes, Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.